Welcome to industryreportstore.com

Need help? +44(0)20 7936 6830

Diabetes market research, reports and industry analysis

mail

Contact us for professional industry advice

Email us or call

+44(0)20 7936 6830
mail

for FREE research alerts
to your inbox

73 Item(s)

Page 1 of 8

  1. Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

    By: GBI Research
    , Published: Dec-2016
    , Product code: GBIHC417MR
    Type 2 diabetes mellitus (T2DM) is a chronic, progressive and serious metabolic disorder characterized by hyperglycemia (high blood glucose levels) and associated with numerous complications and co-morbidities, including cardiovascular, renal and neurodegenerative diseases.
    $6,995.00

  2. Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment

    By: GBI Research
    , Published: Aug-2016
    , Product code: GBIHC413MR
    Diabetes is a chronic metabolic disease characterized by hyperglycemia (high blood glucose levels) that results from defects in insulin secretion, insulin action, or both. Chronic hyperglycemia in diabetic patients is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM). Obesity, meanwhile, is defined as abnormal or excessive body fat accumulation that presents a risk to health.
    $4,995.00

  3. Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

    By: GBI Research
    , Published: Aug-2016
    , Product code: GBIHC421MR
    Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Approximately 90-95% of all diabetics have T2DM.
    $4,995.00

  4. Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies

    By: GBI Research
    , Published: Jun-2016
    , Product code: GBIHC397MR
    Diabetes is a common long-term condition that can lead to a range of disparate and serious complications. It is a lifelong, multi-systemic condition that affects a number of integral organs. Diabetes has a rapidly increasing prevalence – it currently affects 10% of adults globally, and is estimated to become the seventh-leading cause of death by 2030.
    $6,995.00

  5. Global Diabetes Partnering 2010 to 2016

    By: Current Partnering
    , Published: Apr-2016
    , Product code: CP2205dia
    Provides understanding and access to the diabetes partnering deals and agreements entered into by the worlds leading healthcare companies.
    $1,495.00

  6. Global Type 2 Diabetes Market 2016-2020

    By: Technavio
    , Published: Mar-2016
    , Product code: IRTNTR8779
    The report covers the present scenario and the growth prospects of the global type 2 diabetes drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat type 2 diabetes.
    $2,500.00

  7. Global Type 1 Diabetes Market 2016-2020

    By: Technavio
    , Published: Mar-2016
    , Product code: IRTNTR9079
    The report covers the present scenario and the growth prospects of the global type 1 diabetes drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs and biosimilars used to treat and prevent type 1 diabetes.
    $2,500.00

  8. Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Innovative and Diversified Pipeline to Drive Market Growth Despite Patent Expirations

    By: GBI Research
    , Published: Nov-2015
    , Product code: GBIHC372MR
    Type 1 Diabetes Mellitus (T1DM) is a chronic, progressive and serious disease characterized by a destruction or failure of insulin-secreting pancreatic beta cells, usually as a result of an autoimmune response. The resulting insulin deficiency prevents insulin-sensitive cells from carrying out essential glucose metabolism and leads to hyperglycemia (high blood glucose levels). As a result, immediate and lifelong treatment with exogenous insulin therapy is initiated upon diagnosis of T1DM. Exogenous insulin has remained the mainstay of T1DM therapy since it was used to treat the first human patient in 1922.
    $4,995.00

  9. Diabetic Gastroparesis - Pipeline Review, H2 2015

    By: Global Markets Direct
    , Published: Sep-2015
    , Product code: GMDHC7133IDB
    Global Markets Direct’s, ‘Diabetic Gastroparesis - Pipeline Review, H2 2015’, provides an overview of the Diabetic Gastroparesis’s therapeutic pipeline.
    $2,000.00

  10. Type 2 Diabetes - Pipeline Review, H1 2015

    By: Global Markets Direct
    , Published: Feb-2015
    , Product code: GMDHC6121IDB
    Global Markets Direct’s, ‘Type 2 Diabetes - Pipeline Review, H1 2015’, provides an overview of the Type 2 Diabetes’s therapeutic pipeline.
    $2,500.00

73 Item(s)

Page 1 of 8